FDC Limited

FDC Limited, established in 1936, is a prominent Indian pharmaceutical company specializing in the manufacturing and marketing of finished pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company was incorporated as a private limited entity in 1940 and later transitioned to a public limited company, listed on the Bombay and National Stock Exchanges of India in 1996. Headquartered in Mumbai, Maharashtra, FDC Limited operates with a workforce of approximately 6,857 employees. The company's diverse product portfolio includes tablets, capsules, oral liquids, ophthalmic drops, topical preparations, and pediatric-friendly solutions, catering to various therapeutic segments such as anti-infectives, gastrointestinal, ophthalmology, vitamins, minerals, dietary supplements, cardiovascular and anti-diabetic therapies, respiratory care, gynecology, dermatology, and analgesics. FDC Limited markets its products under several well-known brands, including Zifi, Zefu, Zocon, Amodep-AT, Zathrin, Vitcofol, Ziglim, Ziglim-M, Mycoderm, Zoxan, Cotaryl, Pyrimon DF, Zipod, Electral, and Enerzal.

FDC Limited operates multiple manufacturing facilities across India, strategically located to enhance production capabilities and meet global demand. These facilities are situated in Roha, Waluj, and Sinnar in Maharashtra; Verna in Goa; and Baddi in Himachal Pradesh. The Roha plant specializes in the production of pharmaceutical dosage forms, food products, and bulk drugs for the anti-rheumatic, anti-asthmatic, ophthalmic, and ENT segments. FDC Limited's manufacturing plants are accredited by various international regulatory bodies, including the US FDA, UK MHRA, MCC RSA, and the UAE, ensuring compliance with global quality standards.

FDC Limited's leadership team comprises experienced professionals dedicated to steering the company towards sustained growth and innovation. The key executives include:

• Ameya Ashok Chandavarkar – Chief Executive Officer of International Business and Executive Director.

• Dr. Nandan Mohan Chandavarkar – Joint Managing Director and Executive Director.

• Mohan Anand Chandavarkar – Business Head, Managing Director, and Director.

• Vishal Shah – Chief Financial Officer.

• Shashank Vyapari – Vice President of Technical and Operations.

• Sanjay B. Jain – Vice President of Corporate Finance.

• Varsharani Rajaram Katre C.S. – Legal Head, Compliance Officer, and Company Secretary.

• Zafrullah Khan – Senior Vice President – Human Resources.

• Mayank Tikkha – Senior Vice President – Business Development.

• Shivaji S. Nalawade – Senior Vice President – Distribution.

This leadership team is instrumental in driving FDC Limited's strategic initiatives and maintaining its position as a leading player in the pharmaceutical industry.

FDC Limited has established a significant presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has achieved accreditations from the US FDA, UK MHRA, MCC RSA, and the UAE, among others, ensuring compliance with international quality standards. FDC Limited exports its products to approximately 50 countries, reflecting its global reach and adherence to stringent regulatory requirements. The company's manufacturing facilities are approved by various international regulatory bodies, including the US FDA, UK MHRA, MCC RSA, and the UAE, ensuring compliance with global quality standards. This extensive regulatory compliance underscores FDC Limited's commitment to delivering high-quality pharmaceutical products to markets worldwide.

FDC Limited has strategically expanded its footprint into emerging markets across Africa, Latin America, and Southeast Asia. The company's adherence to international quality standards, as evidenced by its accreditations from the US FDA, UK MHRA, MCC RSA, and the UAE, facilitates its entry into these regions. By obtaining WHO prequalification, FDC Limited enhances its ability to supply essential medicines to these markets, thereby contributing to global health initiatives and expanding its market presence.

FDC Limited's geographic strategy demonstrates a balanced approach to market diversification and risk management. The company's export activities span approximately 50 countries, indicating a broad international presence. This extensive reach mitigates concentration risk and positions FDC Limited to capitalize on growth opportunities across diverse regions. The company's adherence to international quality standards, as evidenced by its accreditations from the US FDA, UK MHRA, MCC RSA, and the UAE, further supports its strategic direction in global markets.

FDC Limited's manufacturing facilities are registered with the US FDA, reflecting the company's commitment to meeting stringent regulatory standards. The company has filed multiple Abbreviated New Drug Applications (ANDAs) and Drug Master Files (DMFs), facilitating the approval of its generic pharmaceutical products in the United States. FDC Limited's facilities have undergone inspections by the US FDA, resulting in favorable outcomes that affirm the company's adherence to Good Manufacturing Practices (GMP). This regulatory compliance underscores FDC Limited's dedication to delivering high-quality pharmaceutical products to the US market.

FDC Limited's manufacturing facilities are certified with WHO-GMP and EU GMP, demonstrating the company's commitment to maintaining high-quality manufacturing standards. These certifications enable FDC Limited to supply pharmaceutical products to international markets that require compliance with WHO and EU GMP guidelines. The company's adherence to these standards ensures the safety, efficacy, and quality of its products, reinforcing its reputation as a reliable pharmaceutical manufacturer.

FDC Limited holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), the national regulatory authority in India, authorizing the production of pharmaceutical formulations. The company has obtained approvals from state drug controllers, ensuring compliance with regional regulations. FDC Limited possesses export No Objection Certificates (NOCs), facilitating the export of its pharmaceutical products to various international markets. These regulatory approvals affirm FDC Limited's adherence to national and international standards, enabling the company to operate effectively within India's regulatory framework.

As of March 2026, FDC Limited has not been subject to any Form 483 observations, warning letters, or import alerts from the US FDA. This indicates that the company's manufacturing facilities have consistently met the FDA's stringent quality standards during inspections. The absence of such regulatory actions reflects FDC Limited's commitment to maintaining high-quality manufacturing practices and compliance with international regulatory requirements.

FDC Limited operates in a competitive pharmaceutical industry, facing competition from both domestic and international companies. In the anti-infective segment, FDC Limited's top products include Ofloxacin, Ciprofloxacin, and Gentamicin, with export values of $5.5 million, $4.8 million, and $1.6 million, respectively. These products hold market shares of 1.9%, 1.6%, and 3.1%, respectively, indicating a strong presence in the market. The company's focus on high-quality formulations and adherence to international standards positions it favorably against competitors in overlapping categories.

FDC Limited's key differentiators include its extensive product portfolio, which encompasses over 300 products across various therapeutic segments, and its strong presence in the oral rehydration solutions (ORS) and ophthalmic therapy markets. The company's manufacturing facilities are accredited by international regulatory bodies, including the US FDA, UK MHRA, MCC RSA, and the UAE, ensuring compliance with global quality standards.